Literature DB >> 10942793

Protease nexin-2/Amyloid beta-protein precursor regulates factor VIIa and the factor VIIa-tissue factor complex.

F Mahdi1, A Rehemtulla, W E Van Nostrand, S P Bajaj, A H Schmaier.   

Abstract

Protease nexin-2/amyloid beta-protein precursor (PN-2/AbetaPP) and its Kunitz protease inhibitory (KPI) domain were characterized as inhibitors of factor VIIa (FVIIa) and factor VIIa-tissue factor complex (FVIIa-TF). PN-2/AbetaPP and KPI domain inhibited FVIIa with an apparent K(i) of 1.1+/-0.2x 10(-7) M and 1.5+/-0.1x10(-7) M, respectively. When soluble tissue factor (TF(1-219)) was present, there was increased FVIIa inhibition by PN-2/AbetaPP or KPI domain (K(i)=7.8+/-0.3x10(-8) M and 6.8+/-0.6x10(-8) M, respectively). When relipidated tissue factor (TF(1-243)) was present, the K(i) of FVIIa inhibition by PN-2/AbetaPP increased 4.7-fold further. PN-2/AbetaPP complexed with FVIIa, as shown on gel filtration and solid phase binding assay. The apparent second-order rate constant of inhibition of FVIIa by PN-2/AbetaPP in the absence of TF(1-219) was less than that of the FVIIa-TF(1-219) complex. Antithrombin in the absence of TF(1-219) also had a lower apparent second-order rate constant of inhibition than in its presence. In a mixture that included FVIIa, relipidated TF(1-243) and factor X, PN-2/AbetaPP or KPI domain had an IC(50) at 65 and 250 nM, respectively; antithrombin and heparin (1 U/mL) had an IC(50) of 12.8 nM. These data indicate that tissue factor promoted the inhibition of FVIIa by PN-2/AbetaPP or KPI domain, but antithrombin was a better inhibitor of soluble FVIIa-TF in extrinsic tenase.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942793     DOI: 10.1016/s0049-3848(00)00245-0

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

1.  Mechanisms and specificity of factor XIa and trypsin inhibition by protease nexin 2 and basic pancreatic trypsin inhibitor.

Authors:  Duraiswamy Navaneetham; Dipali Sinha; Peter N Walsh
Journal:  J Biochem       Date:  2010-07-20       Impact factor: 3.387

2.  Protease nexin-2/amyloid beta-protein precursor limits cerebral thrombosis.

Authors:  Feng Xu; Judianne Davis; Jianting Miao; Mary Lou Previti; Galina Romanov; Kelly Ziegler; William E Van Nostrand
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

Review 3.  Platelets and Alzheimer's disease: Potential of APP as a biomarker.

Authors:  Geneviève Evin; Qiao-Xin Li
Journal:  World J Psychiatry       Date:  2012-12-22

4.  Mutation of the Kunitz-type proteinase inhibitor domain in the amyloid β-protein precursor abolishes its anti-thrombotic properties in vivo.

Authors:  Feng Xu; Judianne Davis; Michael Hoos; William E Van Nostrand
Journal:  Thromb Res       Date:  2017-05-04       Impact factor: 3.944

Review 5.  The influence of the amyloid ß-protein and its precursor in modulating cerebral hemostasis.

Authors:  William E Van Nostrand
Journal:  Biochim Biophys Acta       Date:  2015-10-27

6.  Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants.

Authors:  Hsiu-Hui Chen; Cristina P Vicente; Li He; Douglas M Tollefsen; Tze-Chein Wun
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

7.  Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets.

Authors:  Tyler A Kokjohn; Gregory D Van Vickle; Chera L Maarouf; Walter M Kalback; Jesse M Hunter; Ian D Daugs; Dean C Luehrs; John Lopez; Daniel Brune; Lucia I Sue; Thomas G Beach; Eduardo M Castaño; Alex E Roher
Journal:  Biochim Biophys Acta       Date:  2011-07-20

Review 8.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.